LIMN (Liminatus Pharma) Other Financing: $-2.56 Mil (TTM As of Mar. 2026)


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.12
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Other Financing?

Liminatus Pharma LIMN +3.99% 13 Other Financing is $-2.56 Mil as of Mar. 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Liminatus Pharma's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Liminatus Pharma's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.56 Mil.

Liminatus Pharma Other Financing Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Other Financing Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Financing
0.00 0.00 0.00 -2.56

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2.56 0.00 0.00 0.00
LIMN
13GF Score
Liminatus Pharma Inc LIMN
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-2.56 Mil mean?
Liminatus Pharma (LIMN) has a Other Financing of $-2.56 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Liminatus Pharma and its competitors.
Is Liminatus Pharma's Other Financing too high?
Liminatus Pharma's current Other Financing is $-2.56 Mil. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Other Financing compare to GNPX and PCSA?
Liminatus Pharma's Other Financing of $-2.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Liminatus Pharma and its competitors. Liminatus Pharma's current Other Financing is $-2.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Other Financing of $-2.56 Mil. The current Other Financing is $-2.56 Mil. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Other Financing is $-2.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price